300 TECHNOLOGY SQUARE, CAMBRIDGE, MA
Investor Presentation
Annual Meeting Results: Election of Class II Directors - Sujay Kango, Anne Mc...
Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
Annual Report to Security Holders
Dianthus Therapeutics Enters Underwriting Agreement for $593.5M Offering
Highlights Recent Business Achievements, Including Go Decision for Phase 3 Captivate CIDP Trial, and Reports Q4 and FY 2025 Financial Results
Q2
Q1
FY 2025
Q3
FY 2024
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report